Angiogenic and antiangiogenic gene therapy

Gene Therapy

Volumn 12, Issue , 2005, Pages S159-S169

  Malecki, M ^a,b   Kolsut, P ^c   Proczka, R ^b  

^a INSTITUTE OF ONCOLOGY   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

^c INSTITUTE OF CARDIOLOGY   (Poland)

Author keywords

Angiogenesis; Cancer; Ischemic diseases

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; ANGIOGENIN; ANGIOPOIETIN; ANGIOSTATIN; CANSTATIN; ENDOSTATIN; FIBROBLAST GROWTH FACTOR; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 8; LEPTIN; MASPIN; MATRIX METALLOPROTEINASE INHIBITOR; NAKED DNA; PARVOVIRUS VECTOR; PLASMID DNA; PLASMID VECTOR; PLATELET DERIVED ENDOTHELIAL CELL GROWTH FACTOR; PLEIOTROPHIN; PROLACTIN DERIVATIVE; PROLIFERIN; RESTIN; RETINA S ANTIGEN; SCATTER FACTOR; THROMBOCYTE FACTOR 4; TRANSFORMING GROWTH FACTOR; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; ARTERY DISEASE; CANCER; CARDIOVASCULAR DISEASE; CLINICAL STUDY; CLINICAL TRIAL; CONFERENCE PAPER; CORONARY ARTERY DISEASE; DRUG POTENTIATION; DRUG SCREENING; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE THERAPY; GENETIC TRANSFECTION; HEART MUSCLE; HUMAN; MOLECULAR BIOLOGY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; SKELETAL MUSCLE; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; EXTREMITIES; GENE THERAPY; HUMANS; ISCHEMIA; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; PLASMIDS; VASCULAR DISEASES;

PARVOVIRUS;

EID: 27544491447     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/sj.gt.3302621     Document Type: Article

References (142)

1. Kohn DB et al. T lymphocytes with a normal ADA gene accumulate after transplantation of transduced autologous umbilical cord blood CD34+ cells in ADA-deficient SCID neonates. Nat Med 1998; 4: 775-780.
2. http:llwww.wiley.co.uk.
3. Verma IM, Somia N. Gene therapy - promises, problems and prospects. Nature 1997; 389: 239-242.
4. Gobhans H. Gene therapy - when a simple concept meets a complex reality. Funct Integr Genomics 2000; 1: 142-145.
5. Rochlitz CF. Gene therapy of cancer. Swiss Med Wkly 2001; 131: 4-9.
6. Gutierrez AA, Lemoine NR, Sikora K. Gene therapy for cancer. Lancet 1992; 339: 715-721.
7. Miller AD. Human gene therapy comes of age. Nature 1992; 357: 455-460.
8. Mulligan RC. The basic science of gene therapy. Science 1993; 260: 926-932.
9. Philips MI. Somatic gene therapy for hypertension. Braz J Med Biol Res 2000; 33: 715-721.
10. Khurana R, Martin JF, Zachary I. Gene therapy for cardiovascular disease: a case for cautious optimism. Hypertension 2001; 38: 1210-1216.
11. Morhishita R. Recent progress in gene therapy for cardiovascular disease. Circ J 2002; 66: 1077-1086.
12. Isner JM, Vale PR, Symes JF, Losordo DW. Assessment of risks associated with cardiovascular gene therapy in human subjects. Circ Res 2001; 89: 389-400.
13. Isner JM, Ashara T. Therapeutic angiogenesis. Front Biosci 1998; 3: 49-69.
14. Harjai KJ, Chowdhurry P, Grines CL. Therapeutic angio- genesis: a fantastic new adventure. J Interven Cardiol 2002; 15: 223-230.
15. Yla-Harttuala S, Alitalo K. Gene transfer as a tool to induce therapeutic vascular growth. Nat Med 2003; 6: 694-701.
16. Farrara N, Garber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 6: 669-676.
17. Ferrara N et al. The vascular endothelial growth factor family of polypeptides. J Cell Biochem 1991; 42: 211-218.
18. Proczka RM, Polanski JA, Malecki M, Wikiel K. The significance of vascular endothelial growth factor in the neoangiogenesis process. The role of hypoxia in the endothelial cells proliferation process and in the formation of collateral circulation. Acta Angiol 2003; 9: 143-149.
19. Connolly DT. Vascular permeability factor: a unique regulator of blood vessel function. J Cell Biochem 1991; 47: 219-223.
20. Scapaticci FA. Machanisms and future directions for angio- genesis-based cancer therapies. J Clin Oncol 2002; 20: 3906-3927.
21. Zi-Lai Z, Jin-Hui W, Xin-Yuan L. Current strategies and future directions of antiangiogenic tumor therapy. Acta Biochim Biophys Sin 2003; 35: 873-880.
22. Holleb AI, Folkman J. Tumor angiogenesis. CA Cancer J Clin 1972; 22: 226-229.
23. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407: 249-257.
24. Zhang H-T, Harris AL. Anti-angiogenic therapies in cancer clinical trials. Exp Opin Invest Drugs 1998; 7: 1629-1655.
25. Feldman AL, Libutti SK. Progress in antiangiogenic gene therapy of cancer. Cancer 2000; 89: 1181-1194.
26. Hornig C, Weich HA. Soluble VEGF receptors. Angiogenesis 1999; 3: 33-39.
27. Brantley DM et al. Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo. Oncogene 2002; 10: 7011-7026.
28. Kendall RL, Thomas KA. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA 1993; 90: 10705-10709.
29. Malecki M et al. Antiangiogenic gene therapy: application of soluble FLT-1 receptor. Adv Clin Exp Med 2004; 13: 227-233.
30. Yancopoulos GD et al. Vascular-specific growth factors and blood vessel formation. Nature 2000; 407: 242-248.
31. Battegay EJ. Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects. Mol Med 1995; 73: 333-346.
32. Kutryk MJB, Stewart DJ. Angiogenesis of the heart. Microsc Res 2003; 60: 138-158.
33. Davidson B, Reich R, Risberg B, Nesland JM. The biological role and regulation of matrix metalloproteinases (MMP) in cancer. Arkh Patol 2002; 64: 47-53.
34. Kuzuya M, Iguchi A. Role of matrix metalloproteinases in vascular remodeling. J Atheroscler Thromb 2003; 10: 275-282.
35. Vaisman N, Gospodarowicz D, Neufeld G. Characterization of the receptors for vascular endothelial growth factor. J Biol Chem 1990; 265: 19461-19466.
36. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micro- metastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1995; 1: 149-153.
37. Bohle AS, Kalthoff H. Molecular mechanisms of tumor metastasis and angiogenesis. Langenbeck's Arch Surg 1999; 384: 133-140.
38. Szala S, Radzikowski C. Molecular basis of neoplastic angiogenesis. J Oncol 1997; 47: 1-19.
39. Sheta EA, Harding MA, Conaway MR, Theodorescu D. Focal adhesion kinase, Rap1, and transcriptional induction of vascular endothelial growth factor. J Natl Cancer Inst 2000; 92: 1065-1073.
40. Yu JL et al. Oncogenes as regulators of tissue factor expression in cancer: implications for tumor angiogenesis and anti-cancer therapy. Semin Thromb Hemost 2004; 30: 21-30.
41. Rak J, Yu JL. Oncogenes and tumor angiogenesis: the question of vascular 'supply' and vascular 'demand'. Semin Cancer Biol 2004; 14: 93-104.
42. Rak J, Yu JL, Kerbel RS, Coomber BL. What do oncogenic mutations to do with angiogenesislvascular dependence of tumors? Cancer Res 2002; 62: 1931-1934.
43. Hayes AJ, Li LY, Lippman ME. Antivascular therapy: a new approach to cancer treatment. BMJ 1999; 318: 853-856.
44. Brand K. Cancer gene therapy with tissue inhibitors of metalloproteinases (TIMPs). Curr Gene Ther 2002; 2: 255-271.
45. Semenza GL. Targeting HF-1 for cancer therapy. Nat Rev Cancer 2003; 3: 721-732.
46. Szala S, Szary J, Cichon T, Sochanik A. Antiangiogenic gene therapy in inhibition of metastasis. Acta Biochim Pol 2002; 49: 313-321.
47. Trochon-Joseph V et al. Evidence of antiangiogenic and antimetastatic activities of the recombinant disintegrin domain of metargidin. Cancer Res 2004; 64: 2062-2069.
48. Kuba K et al. HGFlNK4, a four-kringle antagonist of hepatocyte growth factor, is an angiogenesis inhibitor that suppresses tumor growth and metastasis in mice. Cancer Res 2000; 60: 6737-6743.
49. Date K et al. Inhibition of tumor growth and invasion by a four- kringle antagonist (HGFlNK4) for hepatocyte growth factor. Oncogene 1998; 17: 3045-3054.
50. Feldman AL et al. Antiangiogenic gene therapy of cancer utilizing a recombinant adenovirus to elevate systemic endo- statin levels in mice. Cancer Res 2000; 60: 1503-1506.
51. Xiao F et al. A gene therapy for cancer based on the angiogenesis inhibitor, vasostatin. Gene Therapy 2002; 9: 1207-1213.
52. Pike SE et al. Vasostatin, a calreticulin fragment, inhibits angiogenesis and suppresses tumor growth. J Exp Med 1998; 188: 2349-2356.
53. Yao L et al. Effective targeting of tumor vasculature by the angiogenesis inhibitors vasostatin and interleukin-12. Blood 2000; 96: 1900-1905.
54. Yamaguchi S, Iwata K, Shibuya M. Soluble Flt-1 (Soluble VEGFR-1), a potent natural antiangiogenic molecule in mammals, is phylogenetically conserved in avians. Biochem Biophys Res Commun 2002; 291: 554-559.
55. Mori A et al. Soluble Flt-1 gene therapy for peritoneal metastases using HVJ-cationic liposomes. Gene Therapy 2000; 7: 1027-1033.
56. Yang W et al. sFlt-1 gene transfected fibroblsts: a wound- specific gene therapy inhibits local cancer recurrence. Cancer Res 2001; 61: 7840-7845.
57. Hoshida T et al. Gene therapy for pancreatic cancer using an adenovirus vector encoding soluble flt-1 vascular endothelial growth factor receptor. Pancreas 2002; 25: 111-121.
58. Takayama K et al. Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into a remote organ. Cancer Res 2000; 60: 2169-2177.
59. Boehm T, Folkman J, Browder T, O'Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997; 390: 404-407.
60. Simons M et al. Clinical trials in coronary angiogenesis: issues, problems, consensus: an expert panel summary. Circulation 2000; 102: E73-E86.
61. Greco O, Scott SD, Marples B, Dachs GU. Cancer gene therapy: 'delivery, delivery, delivery'. Front Biosci 2002; 7: d1516-d1524.
62. Jain RK. The next frontier of molecular medicine: delivery of therapeutics. Nat Med 1998; 4: 655-657.
63. Nabel GJ. Development of optimized vectors for gene therapy. Proc Natl Acad Sci USA 1999; 96: 324-326.
64. Nettelbeck DM, Jerome V, Muller R. Gene therapy designer promoters for tumour targeting. Trends Genet 2000; 16: 174-181.
65. Krieg AM. Now I know my CpGs. Trends Microbiol 2001; 9: 249-252.
66. Krieg AM, Davis HL. Enhancing vaccines with immune stimulatory CpG DNA. Curr Opin Mol Ther 2001; 3: 15-24.
67. Schleef M, Schmidt T. Animal-free production of ccc-super- coiled plasmids for research and clinical applications. J Gene Med 2004; 6: S45-S53.
68. Stadler J, Lemmens R, Nyhammar T. Plasmid DNA purification. J Gene Med 2004; 6: S54-S66.
69. Wolff JA et al. Expression of naked plasmids by cultured myotubes and entry of plasmids into T tubules and caveolae of mammalian skeletal muscle. J Cell Sci 1992; 103: 1249-1259.
70. Garrett DJ et al. In utero recombinant adeno-associated virus gene transfer in mice, rats, and primates. BMC Biotechnol 2003; 3: 1-16.
71. Park J et al. Long-term correction of globotriaosylceramide storage in Fabry mice by recombinant adeno-associated virusmediated gene transfer. Proc Natl Acad Sci USA 2003; 100: 3450-3454.
72. McTaggart S, Al-Rubeai M. Retroviral vectors for human gene delivery. Biotechnol Adv 2002; 20: 1-31.
73. Marshall E. Gene therapy. Second child in French trial is found to have leukemia. Science 2003; 299: 320.
74. Lehrman S. Virus treatment questioned after gene therapy death. Nature 1999; 401: 517-518.
75. Guha C, Chowdhury NR, Chowdhury JR. Recombinant adenoassociated virus in cancer gene therapy. J Hepatol 2000; 32: 1031-1034.
76. Snyder RO, Flotte TR. Production of clinical-grade recombinant adeno-associated virus vectors. Curr Opin Biotech 2002; 13: 418-423.
77. Blankinship MJ et al. Efficient transduction of skeletal muscle using vectors based on adeno-associated virus serotype 6. Mol Ther 2004; 10: 671-678.
78. Du L et al. Differential myocardial gene delivery by recombinant serotype-specific adeno-associated viral vectors. Mol Ther 2004; 10: 604-608.
79. Schleef M, Schmidt T, Flaschel E. Plasmid DNA for pharmaceutical applications. Dev Biol (Basel) 2000; 104: 25-31.
80. Prazeres DM et al. Large-scale production of pharmaceutical- grade plasmid DNA for gene therapy: problems and bottlenecks. Trends Biotechnol 1999; 17: 169-174.
81. Kendall D, Lye GJ, Levy MS. Purification of plasmid DNA by an integrated operation comprising tangential flow filtration and nitrocellulose adsorption. Biotechnol Bioeng 2002; 79: 816-822.
82. Schluep T, Cooney CL. Purification of plasmids by triplex affinity interaction. Nucleic Acids Res 1998; 26: 4524-4528.
83. http:llwww.emea.eu.int.
84. http:llwww.pheur.org.
85. Jastrzebski Z, Malecki M, Janik P. Study of the bacterial endotoxins level in the angiogenic plasmid DNA preparations. Farmacja Pol 2003; 59: 171-175.
86. Lahijani R et al. Quantitation of host cell DNA contaminate in pharmaceutical-grade plasmid DNA using competitive polymerase chain reaction and enzyme-linked immunosorbent assay. Hum Gene Ther 1998; 9: 1173-1180.
87. Budker V et al. Hypothesis: naked plasmid DNA is taken up by cells in vivo by a receptor-mediated process. J Gene Med 2000; 2: 76-88.
88. Zhang G et al. Efficient expression of naked DNA delivered intraarterially to limb muscles of nonhuman primates. Hum Gene Ther 2001; 12: 427-438.
89. Heller L, Coppola D. Electrically mediated delivery of vector plasmid DNA elicits an antitumor effect. Gene Therapy 2002; 9: 1321-1325.
90. Liu F, Huang L. Electric gene transfer to the liver following systemic administration of plasmid DNA. Gene Therapy 2002; 9: 1116-1119.
91. Sanz G, Satkauskas S, Mir LM. In vivo DNA electrotransfer in skeletal muscle. Methods Mol Biol 2004; 245: 227-236.
92. Hagstrom JE. Plasmid-based gene delivery to target tissues in vivo: the intravascular approach. Curr Opin Mol Ther 2003; 5: 338-344.
93. Herweijer H, Wolff JA. Progress and prospects: naked DANN gene transfer and therapy. Gene Therapy 2003; 10: 453-458.
94. Gollins H, McMahon J, Wells KE, Wells DJ. High-efficiency plasmid gene transfer into dystrophic muscle. Gene Therapy 2003; 10: 504-512.
95. Smith AE. Viral vectors in gene therapy. Annu Rev Microbiol 1995; 49: 807-838.
96. Buttrick PM. Gene therapy in the cardiovascular system: current strategies and practical limitations. J Am Coll Cardiol 1997; 6: 17-21.
97. Templeton NS. Liposomal delivery of nucleic acids in vivo. DNA and Cell Biol 2002; 21: 857-867.
98. Ferrara N, Alitalo K. Clinical application of angiogenic growth factors and their inhibitors. Nat Med 1999; 5: 1359-1364.
99. Hamaway AH, Lee LY, Crystal RG, Rosengart TK. Cardiac angiogenesis and gene therapy: a strategy for myocardial revascularization. Curr Opin Cardiol 1999; 14: 515-522.
100. Rosengart TK, Patel SR, Crystal RG. Therapeutic angiogenesis: proteine and gene therapy delivery strategies. J Cardiovasc Risk 1999; 6: 29-40.
101. Abo-Auda W, Benza RL. Therapeutic angiogenesis: review of current concepts and future directions. J Heart Lung Transplantation 2003; 22: 370-382.
102. Unger EF, Banai S, Shou M. Basic fibroblast growth factor enhances myocardial collateral flow in canine model. Am J Physiol 1994; 266: H1588-H1595.
103. Baffour R et al. Enhanced angiogenesis and growth of collaterals by in vivo administration of recombinant basic fibroblast growth factor in rabbit model of acute lower limb ischemia: dose-response effect of basic fibroblast growth factor. J Vasc Surg 1992; 16: 181-191.
104. Banai S, Jaklitsch MT, Shou M. Angiogenic-induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs. Ciculation 1994; 89: 2183-2189.
105. Hariawala MD, Horowitz JR, Esakof D. VEGF improves myocardial blood flow but produces EDRF-mediated hypotension in porcine hearts. J Surg Res 1996; 63: 77-82.
106. Lopez JJ, Laham RJ, Stamler A. VEGF administration in chronic myocardial ischemia in pigs. Cardiovasc Res 1998; 40: 272-281.
107. Kornowski R, Fuchs S, Leon M, Epstein SE. Delivery strategies to achieve therapeutic myocardial angiogenesis. Circulation 2000; 101: 454-458.
108. Laham RJ, Leimbach M, Chronos NA. Intracoronary administration of recombinant fibroblast growth factor-2 in patients with severe CAD: results of phase I. J Am Coll Cardiol 1999; 33 (Suppl A): 333A.
109. Laham RJ, Sellke FW, Edelman ER. Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary by pass surgery: results of phase I randomized double blind, placebo-controlled trial. Circulation 1999; 100: 1865-1871.
110. Scumacher B, Pecher P, von Specht BU, Stegmann T. Induction of neoangiogenesis in ischemic myocardium by human growth factors: first clinical results of a new treatment of coronary heart disease. Circulation 1998; 97: 645-650.
111. Laham RJ, Selke FW, Edelman ER. Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary by pass surgery: results of phase I randomized double-blind, placebo controlled trial. Circulation 1999; 100: 1865-1871.
112. Hendel RC, Henry TD, Roha-Singh K. Effect of intracoronary recombinant human vascular endothelial growth factor (rhVEGF) on myocardial perfusion: evidence for a dose dependent effect. Circulation 2000; 101: 118-121.
113. Henry TD, Annes BH, Azrin MA. Double-blind placebo controlled trial of recombinant human vascular endothelial growth factor: the VIVA trial. J Am Coll Cardiol 1999; 33 (Suppl A): 384A.
114. Henry TD, Mckendall GR, Azrin MA. VIVA trial: one year follow up. Circulation 2000; 102 (Suppl II): 309.
115. Nicklin SA, Baker AH. Development of targeted viral vectors for cardiovascular gene therapy. Genet Eng (NY) 2003; 15-49.
116. Tsurumi Y, Takeshita S, Chen D. Direct intramuscular gene transfer of naked DNA encoding vascular endothelial growth factor augments collateral development and tissue perfusion. Circulation 1996; 94: 3281-3290.
117. Wolff JA, Malone RW, Williams P. Direct gene transfer into mouse muscle in vivo. Science 1990; 247: 1465-1468.
118. Thompson RB, Rungwerth K, Koch WJ. Gene therapy for heart failure. Ann Med 2004; 36 (Suppl 1): 106-115.
119. Mack ChA, Patel SR, Schwarz EA, Zanzonico P. Biologic bypass with the use of adenovirus-mediated gene transfer of the complementary deoxyribonucleic acid for vascular endothelial growth factor 121 improves myocardial perfusion in the ischemic porcine heart. J Thorac Cardiovasc Surg 1998; 115: 168-177.
120. Asahara T, Bauters Ch, Zeng LuP, Takeshita S. Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo. Circulation 1995; 92: 365-371.
121. Kondoh K, Koyama H, Miyata T, Takato T. Conduction performance of collateral vessels induced by vascular endothelial growth factor or basic fibroblast growth factor. Cardiovasc Res 2004; 61: 132-142.
122. Su H, Lu R, Kan YW. Adeno-associated viral vector-mediated vascular endothelial growth factor gene transfer induces neovascular formation in ischemic heart. Proc Natl Acad Sci USA 2000; 97: 13801-13806.
123. Isner JM, Pieczek A, Schainfeld R. Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patients with ischemic limb. Lancet 1996; 348: 370-374.
124. Baugmgartner I, Pieczek A, Manor O. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel developementin patients with critical ischemia. Circulation 1998; 97: 1114-1123.
125. Losordo DW, Vale PR, Symes JF. Gene therapy for myocardial angiogenesis; initial clinical results with direct myocardial injection of phVEGF165 as a sole therapy for myocardial ischemia. Circulation 1998; 98: 2800-2804.
126. Rosengart TK, Lee LY, Patel SR, Sanborn TA. Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VAGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation 1999; 100: 468-474.
127. Kolsut P et al. Gene therapy of coronary artery disease with phvegf165 - early outcome. Polish Heart J 2003; 59: 373-384.
128. Vale PR et al. Randomised, single-blind, placebo controlled pilot study catheter-based myocardial gene transfer for therapeutic angiogenesis using left ventricular electromechanical mapping in patients with chronic myocardial ischemia. Circulation 2001; 103: 2138-2143.
129. Grines C, Rubanyi GM, Kleiman NS, Marrot P. Angiogenic gene therapy with adenovirus 5 fibroblast growth factor-4 (Ad5FGF-4): a new option for the treatment of coronary artery disease. Am J Cardiol 2003; 92 (Suppl): 24N-31N.
130. Malecki M, Przybyszewska M, Janik P. Construction of a bicistronic proangiogenic expression vector and its application in the experimental angiogenesis in vivo. Acta Biochim Pol 2003; 50: 875-882.
131. Ibukiyama C. Angiogenesis. Angiogenic therapy using fibroblast growth factor and vascular endothelial growth factor for ischemic vascular lesions. Jpn Heart J 1996; 37: 285-300.
132. Whitlock PR et al. Adenovirus-mediated transfer of a minigene expressing multiple isoforms of VEGF is more effective at inducing angiogenesis than comparable vectors expressing individual VEGF cDNAs. Mol Ther 2004; 9: 67-75.
133. Cines DB, Pollak ES, Buck CA. Endothelial cell in physiology and in the pathophysiology of vascular disorders. Blood 1998; 91: 3527-3561.
134. Kessler P. Biobypass, ready for the NOVA Trial. NOGA Lett 2004; 5: 2-4.
135. Yamauchi A et al. Pre-administration of angiopoietin-1 followed by VEGF induces functional and mature vascular formation in a rabbit ischemic model. J Gene Med 2003; 5: 994-1004.
136. Isner JM et al. Arterial gene transfer for therapeutic angiogen- esis in patients with peripheral artery disease. Hum Gene Ther 1996; 7: 959-988.
137. Isner JM et al. Treatment of tromboangiitis obliterans (Buerger's disease) by intramuscular gene transfer of VEGF: preliminary clinical results. J Vasc Surg 1998; 28: 964-975.
138. Baumgartner I et al. Lower-extremity edema associated with gene transfer of naked DNA encoding vascular endothelial growth factor. Ann Intern Med 2000; 132: 880-884.
139. Ozaki H et al. Blockade of vascular endothelial growth factor receptor signaling is sufficient to completely prevent retinal neovascularization. Am J Pathol 2000; 156: 697-707.
140. Celletti FL et al. Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat Med 2001; 7: 425-429.
141. van Weel V et al. Vascular endothelial growth factor overexpression in ischemic skeletal muscle enhances myoglobin expression in vivo. Circ Res 2004; 95: 58-66.
142. Mohler ER et al. Adenoviral-mediated gene transfer of vascular endothelial growth factor in critical limb ischemia: safety results from a phase I trial. Vasc Med 2003; 8: 9-13.